Enanta Pharmaceuticals
ENTA
67 hedge funds and large institutions have $132M invested in Enanta Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 13 increasing their positions, 22 reducing their positions, and 15 closing their positions.
87% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 15
51% more capital invested
Capital invested by funds: $87.3M → $132M (+$44.4M)
24% more funds holding
Funds holding: 54 → 67 (+13)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
41% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.5M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$6.83M |
| 3 |
Millennium Management
New York
|
+$2.61M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.08M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
+$1.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AP
AlpInvest Partners
Amsterdam,
Netherlands
|
-$9.18M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.43M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$5.62M |
| 4 |
SONJCPFA
State of New Jersey Common Pension Fund A
Trenton,
New Jersey
|
-$2.58M |
| 5 |
SCM
Sigma Capital Management
Stamford,
Connecticut
|
-$1.83M |
ENTA Hedge Fund Activity: Q4 2013 in Review
67 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2013, worth a combined $132M — up 51% from $87.3M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ENTA positions and 15 closed out — a net gain of 13 holders — while 13 added to existing stakes and 22 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $31.5M. The largest seller was AlpInvest Partners, cutting an estimated $9.18M.
- 67 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2013, up from 54 in Q3 2013.
- Funds reported $132M of Enanta Pharmaceuticals stock for Q4 2013, up 51% quarter-over-quarter.
- 28 funds opened new Enanta Pharmaceuticals positions in Q4 2013 and 15 closed out, a net change of +13 holders.
- The largest Enanta Pharmaceuticals buyer in Q4 2013 was Fidelity Investments, an estimated $31.5M added.
- The largest Enanta Pharmaceuticals seller in Q4 2013 was AlpInvest Partners, an estimated $9.18M sold.
Based on aggregated 13F filings for Q4 2013.